Castellion A W
Drug Inf J. 1983;17(1):25-9.
The pharmaceutical industry sponsor bears the ultimate responsibility for the verification of all clinical data submitted to the FDA in support of a New Drug Application (NDA). The author provides an overview of a systematic approach to providing quality assurance for all clinical data collected in the course of human trials with research compounds. This systemic approach includes such features as: Standard Operating Procedures Manuals, the development of a quality assurance function within the organization, detailed documentation for all monitoring activities, careful assessment of all clinical research data collected, and an emphasis on preventive measures that can be introduced to assure the quality of subsequent research data.
制药行业赞助商对提交给美国食品药品监督管理局(FDA)以支持新药申请(NDA)的所有临床数据的核实负有最终责任。作者概述了一种系统方法,用于对在使用研究化合物进行人体试验过程中收集的所有临床数据提供质量保证。这种系统方法包括以下特点:标准操作规程手册、在组织内建立质量保证职能、对所有监测活动进行详细记录、对收集的所有临床研究数据进行仔细评估,以及强调可引入的预防措施以确保后续研究数据的质量。